2019
2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W, Investigators T. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC Cardiovascular Interventions 2019, 12: 1679-1687. PMID: 31129092, DOI: 10.1016/j.jcin.2019.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary ThrombosisDrug-Eluting StentsDual Anti-Platelet TherapyEuropeEverolimusFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureXIENCE stentXience groupLesion failurePrimary endpointClinical outcomesIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionLong-term outcomesDurable polymer everolimusBiodegradable Polymer SirolimusAbluminal grooveFIREHAWK stentLesion revascularizationCardiac deathComparable safetyStent thrombosisMyocardial infarctionClinical trialsEfficacy profileNoninferiority trialLandmark analysis
2018
Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EuroIntervention 2018, 13: 1554-1560. PMID: 29131802, DOI: 10.4244/eij-d-17-00886.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAcute Coronary SyndromeAdultClinical Decision-MakingCoronary Artery DiseaseCoronary ThrombosisFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPractice Patterns, Physicians'Product Surveillance, PostmarketingProspective StudiesProsthesis DesignRegistriesRisk FactorsTime FactorsTreatment OutcomeUnited KingdomConceptsBioresorbable vascular scaffoldDe novo coronary lesionsOne-year clinical outcomesIndependent clinical events committeeMajor adverse cardiac eventsAbsorb bioresorbable vascular scaffoldCareful implantation techniqueAdverse cardiac eventsNovo coronary lesionsTarget lesion failureAcute coronary syndromeClinical events committeeB2/CCareful patient selectionContemporary drug-eluting stentsDrug-eluting stentsVascular scaffoldsSmall vessel sizeDefinite STCoronary syndromeLesion failureCardiac eventsPatient ageReal-world practiceBVS implantation
2016
Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials
Bouras G, Jhamnani S, Ng VG, Haimi I, Mao V, Deible R, Cao S, Sudhir K, Lansky AJ. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization And Cardiovascular Interventions 2016, 89: 984-991. PMID: 27545721, DOI: 10.1002/ccd.26711.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsLong coronary lesionsTarget lesion failurePercutaneous coronary interventionAcademic Research ConsortiumMean lesion lengthCoronary lesionsXIENCE VCoronary interventionStent thrombosisLesion lengthRate of TLFControl groupSecond generation drug eluting stentsLong lesion groupAdverse cardiac eventsProbable stent thrombosisPrimary outcome measureCoronary stent systemDrug eluting stentsLesion failureCardiac eventsPooled analysisWorse outcomesLesion groupWhat the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis
Lansky AJ, Ng VG. What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis. Circulation Cardiovascular Interventions 2016, 9: e003861. PMID: 27162219, DOI: 10.1161/circinterventions.116.003861.Peer-Reviewed Original Research
2013
Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial programThree-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study.
Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky AJ, Bichalska M, Meis S, Verheye S. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention 2013, 9: 573-81. PMID: 24058075, DOI: 10.4244/eijv9i5a93.Peer-Reviewed Original ResearchConceptsTarget lesion revascularisationIschaemia-driven target lesion revascularisationMajor adverse cardiac eventsSecondary safety endpointStent thrombosisMyocardial infarctionBifurcation lesionsAXXESS stentSafety endpointClinical outcomesBiolimus A9De novo coronary bifurcation lesionsThree-year clinical outcomesNew-generation drug-eluting stentsThree-year clinical resultsCumulative stent thrombosisProbable ST eventsAdverse cardiac eventsSingle-arm trialImproved clinical outcomesTrue bifurcation lesionsCoronary bifurcation lesionsDrug-eluting stentsPromising treatment strategyPresent large studyA randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013, 9: 75-83. PMID: 23685298, DOI: 10.4244/eijv9i1a12.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedAnalysis of VarianceAntineoplastic AgentsChinaChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansLeast-Squares AnalysisMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsIschaemia-driven target lesion revascularisationStent late lumen lossTarget vessel myocardial infarctionLate lumen lossTarget lesion failureSingle de novo coronary lesionsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsPrimary endpointCardiac deathI trialNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentSingle de novo native coronary lesionsDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsNine monthsNative coronary lesionsProbable stent thrombosisTarget lesion revascularisationVessel myocardial infarctionSirolimus-eluting stentsNon-inferiority trialLesion revascularisationEES groupPlaque shift and distal embolism in patients with acute myocardial infarction
Wu X, Maehara A, He Y, Xu K, Oviedo C, Witzenbichler B, Lansky AJ, Dressler O, Parise H, Stone GW, Mintz GS. Plaque shift and distal embolism in patients with acute myocardial infarction. Catheterization And Cardiovascular Interventions 2013, 82: 203-209. PMID: 22936619, DOI: 10.1002/ccd.24644.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary ThrombosisCoronary VesselsCreatine Kinase, MB FormEmbolismFemaleHumansLinear ModelsMaleMiddle AgedMyocardial InfarctionNo-Reflow PhenomenonPercutaneous Coronary InterventionPlaque, AtheroscleroticPredictive Value of TestsProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesStentsTreatment OutcomeUltrasonography, InterventionalConceptsThrombus groupCK-MBAngiographic thrombusPlaque shiftReference segmentsAxial plaque redistributionDistal plaque embolizationDistal reference segmentsHORIZONS-AMI trialNative coronary lesionsM volumeAcute myocardial infarctionVolumetric intravascular ultrasoundBare metal stentsOverall plaque volumePeriprocedural elevationPlaque redistributionDistal embolismCoronary lesionsPlaque embolizationMyocardial infarctionStent implantationPlaque volumeInfarction lesionsIntravascular ultrasound
2011
Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes
Palmerini T, Dangas G, Mehran R, Caixeta A, Généreux P, Fahy MP, Xu K, Cristea E, Lansky AJ, Stone GW. Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation Cardiovascular Interventions 2011, 4: 577-584. PMID: 22028471, DOI: 10.1161/circinterventions.111.963884.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, Balloon, CoronaryComorbidityCoronary ThrombosisCoronary VesselsDiabetes Mellitus, Type 1Drug-Eluting StentsElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHumansMaleMetalsMiddle AgedPredictive Value of TestsPrevalenceProspective StudiesRisk FactorsStentsConceptsSegment elevation acute coronary syndromesElevation acute coronary syndromeProbable stent thrombosisAcute coronary syndromeStent thrombosisNSTE-ACSCardiac mortalityCoronary syndromeIndependent predictorsStent implantationDiseased vesselsUrgent Intervention Triage Strategy (ACUITY) trialDynamic ST segment changesIncidence of STInsulin-treated diabetes mellitusElective stent implantationEarly stent thrombosisPercutaneous coronary interventionST-segment changesBare metal stentsDrug-eluting stentsLate stent thrombosisST-segment deviationAcute CatheterizationAntithrombotic regimensImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsPrognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. JACC Cardiovascular Interventions 2011, 4: 769-777. PMID: 21777885, DOI: 10.1016/j.jcin.2011.02.019.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionAcute coronary syndromeACUITY trialStent thrombosisMyocardial infarctionACS patientsCoronary interventionIndependent predictorsHigh-risk acute coronary syndromesSegment elevation acute coronary syndromesElevation acute coronary syndromeHigh-risk ACS patientsIndependent angiographic core laboratoryEpicardial coronary flowEarly invasive strategyRisk of deathHigh-risk populationAngiographic core laboratoryHigh rateBaseline angiographyCoronary syndromeIschemic complicationsAdjunctive pharmacotherapyCoronary thrombusPrognostic importanceFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictorsLow Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials
BEZENEK S, HERMILLER J, LANSKY A, YAQUB M, HATTORI K, CAO S, SOOD P, SUDHIR K. Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials. Journal Of Interventional Cardiology 2011, 24: 326-341. PMID: 21443551, DOI: 10.1111/j.1540-8183.2011.00628.x.Peer-Reviewed Original ResearchConceptsEverolimus-Eluting Coronary Stent SystemDual antiplatelet therapyXIENCE VST ratesRisk factorsLow stent thrombosis ratesSingle-arm clinical trialOccurrence of STStent thrombosis riskAcademic Research ConsortiumStent thrombosis ratesPotential risk factorsCoronary stent systemLow ST ratesHigh compliance rateSPIRIT FIRSTAntiplatelet therapyThrombosis rateSPIRIT trialComplex patientsThrombosis riskClinical trialsStent systemThin strut designDrug usageRationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction
Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 2011, 161: 478-486.e7. PMID: 21392601, DOI: 10.1016/j.ahj.2010.10.006.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsCoronary OcclusionCoronary ThrombosisEndpoint DeterminationHirudinsHumansImmunoglobulin Fab FragmentsInfusions, Intra-ArterialMagnetic Resonance Imaging, CineMyocardial InfarctionPatient SelectionPeptide FragmentsPlatelet Aggregation InhibitorsRecombinant ProteinsResearch DesignThrombectomyConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPrimary PCIAnterior ST-elevation myocardial infarctionExport aspiration catheterPercutaneous coronary interventionLocal infusionThrombus aspirationInfarct sizeINFUSE-AMIEnd pointCoronary interventionAspiration catheterMyocardial infarctionInfusion catheterAnterior ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionSingle-blind randomized studyCardiac magnetic resonance imagingMyocardial infarction 0Mid-left anteriorPrimary end pointSafety end pointSecondary end pointsST-segment resolutionLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). The American Journal Of Cardiology 2011, 107: 833-840. PMID: 21247538, DOI: 10.1016/j.amjcard.2010.10.069.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedPaclitaxelProspective StudiesSingle-Blind MethodSirolimusSurvival RateTreatment OutcomeTubulin ModulatorsUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiovascular eventsSPIRIT III trialAdverse cardiovascular eventsCardiovascular eventsIII trialsPrimary clinical end pointLimited long-term dataTarget lesion revascularizationTarget vessel failureEvent-free survivalClinical end pointsEverolimus-Eluting StentsLong-term safetyLesion revascularizationCardiac deathCoronary arteryMyocardial infarctionSPIRIT IIClinical trialsEfficacy profileUnited States sitesLandmark analysisTerm safetyXIENCE VStrut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction
Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, Stone GW. Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction. Circulation 2011, 123: 274-281. PMID: 21220730, DOI: 10.1161/circulationaha.110.963181.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsOptical coherence tomographyStrut coverageCoherence tomographyBMS lesionsMyocardial infarctionPE lesionsStent strutsMetal stentsPrimary percutaneous coronary interventionAcute Myocardial Infarction trialMyocardial Infarction trialPrespecified end pointElevation myocardial infarctionIndependent core laboratoryPercutaneous coronary interventionStent strut coverageAcute myocardial infarctionSubsequent stent thrombosisDrug-eluting stentsFormal substudyHarmonizing OutcomesStent assignment
2009
A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis
Liu X, Doi H, Maehara A, Mintz GS, de Ribamar Costa J, Sano K, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Collins M, Fahy M, Stone GW, Moses JW, Leon MB, Mehran R. A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis. JACC Cardiovascular Interventions 2009, 2: 428-434. PMID: 19463466, DOI: 10.1016/j.jcin.2009.01.011.Peer-Reviewed Original ResearchConceptsStent thrombosis groupIntravascular ultrasound findingsMinimum stent areaStent areaThrombosis groupISR groupStent thrombosisUltrasound findingsIntravascular Ultrasound ComparisonProximal stent segmentISR patientsDES thrombosisEdge dissectionStent underexpansionUltrasound comparisonStent fractureThrombosis patientsEarlier drugsStent restenosisThrombosisPatientsStent expansionStent segmentRestenosisLesionsEarly Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents
Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 687-698. PMID: 19171852, DOI: 10.1161/circulationaha.108.804203.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsAcute coronary syndromeGlycoprotein IIb/IIIa inhibitorsEarly stent thrombosisStent thrombosisCoronary syndromeBare metal stentsDrug-eluting stentsThienopyridine administrationAngiographic resultsHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialMetal stentsHigher baseline hemoglobin levelsInsulin-requiring diabetes mellitusQuantitative coronary angiographic analysisStent minimal lumen diameterAntiplatelet drug useBaseline renal insufficiencyCoronary angiographic analysisSuboptimal angiographic resultsBaseline hemoglobin levelDefinite stent thrombosisProbable stent thrombosisHigh-risk patients
2007
Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings
Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Frankin-Bond T, Stone GW, Moses JW, Leon MB, Mehran R. Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings. The American Journal Of Cardiology 2007, 101: 58-62. PMID: 18157966, DOI: 10.1016/j.amjcard.2007.07.049.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBare metal stentsClinical outcomesTarget vessel revascularization rateMultiple drug-eluting stentsAcute stent thrombosisVessel revascularization rateDe novo lesionsTarget vessel revascularizationPercutaneous coronary interventionCoronary artery narrowingImplanted stent diameterNovo lesionsProspective registryRevascularization ratesVessel revascularizationBMS implantationCoronary interventionDES implantationConsecutive patientsArtery narrowingStent thrombosisMyocardial infarctionStent restenosisStent diameterImpact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial)
Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, Stone GW. Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2007, 99: 1055-1061. PMID: 17437727, DOI: 10.1016/j.amjcard.2006.11.066.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathCoronary AngiographyCoronary RestenosisCoronary ThrombosisCreatine KinaseFemaleFollow-Up StudiesForecastingHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet CountPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsTreatment OutcomeConceptsPrimary percutaneous coronary interventionBaseline platelet countAcute myocardial infarctionPrimary PCIHigher baseline platelet countPercutaneous coronary interventionPlatelet countCoronary interventionMyocardial infarctionAngiographic success rateTarget vessel thrombosisPowerful independent predictorMedian platelet countRole of plateletsCADILLAC trialCardiac mortalityAngiographic outcomesIndependent predictorsAngiographic resultsHighest quartileMultivariable analysisVessel thrombosisVascular responsesReinfarctionPatients